Clinical trials: MAFLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- ENDOCARE-SCREE (NCT07336563)
- Where
- Poland
- Volunteers
- 10,000 people
- Sponsor
- Jarosław Drobnik
Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches.
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
- Trial name
- METAfoie (NCT06764056)
- Testing
- semaglutide, Diet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Metabolic-associated Fatty Liver Disease (MAFLD)
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease…
- Trial name
- NCT06078722
- Where
- 7 sites in Kazakhstan
- Volunteers
- 264 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Noninvasive Assessment of Metabolic Associated Fatty Liver Disease (MAFLD) in Chinese Population
Attenuation imaging (ATI) technology independently developed by Canon medical is a non-invasive examination technology for quantitative detection and analysis of liver steatosis.
- Trial name
- NCT04551716
- Where
- China
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Detect the Significance of Remnant Cholesterol in Detection Severity of MAFLD
The Significance of Remnant Cholesterol and Carotid Intima Media Thickness in Patients With MAFLD
1. To detect the significance of remenant cholesterol in detection severity of MAFLD 2. To detect the significance of carotid intima-media thickness in MAFLD
- Trial name
- MAFLD (NCT06449092)
- Testing
- Lipid profile
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Fatty Liver Disease
Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
This study consists of 2 parts: Part 1: a cross-sectional study, looking at the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) among nurses in Hospital Canselor Tuanku Muhriz (HCTM).
- Trial name
- NCT05880316
- Testing
- Intermittent Fasting
- Where
- Malaysia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
NASH, NAFLD
RE and Probiotics in MAFLD/NAFLD
This project aims to evaluate the roles of the autonomic nervous system (ANS) and gut microbiota as correlates of clinical improvement in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver…
- Conditions
- NASH, NAFLD, MAFLD
- Trial name
- NCT06563921
- Testing
- physical exercise programme, probiotics supplementation
- Volunteers
- 180 people
- Sponsor
- Nicolaus Copernicus University
Steatohepatitis, Nonalcoholic
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
Primary outcome Screen for MAFLD among patients attending to the Nutrition clinic in Al Rajhi hospital. Secondary outcome Determining the degrees of fibrosis and steatosis in patients with MAFLD Determining the rate of obesity…
- Trial name
- NCT04861012
- Testing
- Ultrasound
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
NAFLD, Diet Habit
Exploring the Mechanism of Dietary Pattern Improving MAFLD
investigators plan to observe the changes of biochemical indicators, body composition, gut microbiota, metabolomics in patients at different periods through balanced diet and Low-carbohydrate diet, so as to determine the…
- Trial name
- NCT05960396
- Testing
- Diet intervention
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Liver Cirrhosis, Obesity
Impact of Weight Loss in Cirrhosis With Obesity and MAFLD
Nutrition therapy is the cornerstone of medical therapy in patients with cirrhosis. 70% compensated patients with Chronic Liver Disease (CLD) are overweight or obese.
- Trial name
- WELCOME (NCT05104541)
- Testing
- Weight loss
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic-associated Fatty Liver Disease
Efficacy and Safety of Rifaximin in Treating MAFLD
Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.
- Trial name
- NCT07185932
- Testing
- Rifaximin (Xifaxan)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045.
- Trial name
- NCT05597709
- Testing
- Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
- Where
- China
- Volunteers
- 2,900 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Metabolic Dysfunction-Associated Fatty Liver Disease
Evaluate the Effect of Synbiotics on MAFLD
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Available data indicates that probiotics may regulate the gut microbiota, while Vitamin E and omega 3 are safe and effective at…
- Trial name
- MAFLD-RCT (NCT06537882)
- Testing
- G-NiiB synbiotics formula (SLP07)
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- GenieBiome Limited
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
Fatty Liver Disease, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF
Ultrasound Derived Fat Fraction (UDFF) Evaluation of Metabolic Related Fatty Liver Disease (MAFLD) in obesity Patients Metabolic fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is the most…
- Trial name
- NCT06097338
- Testing
- bariatric surgery (BS)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Liver Disease Chronic, Fibrosis, Liver
Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification
Liver stiffness is a marker for scarring of the liver, which occurs after damage from various liver conditions. Scarring prevents normal liver function and can lead to liver failure.
- Conditions
- Liver Disease Chronic, Fibrosis, Liver, Liver Steatoses, Liver Fat
- Trial name
- NCT06111859
- Testing
- Ultrasound based Elastography and fat quantification
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College Hospital NHS Trust